NICOLAS CHRONOS
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- EATONTON, GA
- NPI
- 1427057165
- Received
- $912,351 in 227 records, 2019 to 2025; ownership interests with $27,820 invested
- As principal investigator
- $1,464,618 of research payments to others in 670 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 26 | $18,166 |
| 2024 | General payment | 42 | $890,542 |
| 2024 | Ownership or investment interest | 1 | $0 |
| 2023 | General payment | 44 | $1,065 |
| 2023 | Ownership or investment interest | 1 | $27,820 |
| 2022 | General payment | 25 | $429 |
| 2022 | Ownership or investment interest | 1 | $0 |
| 2021 | General payment | 31 | $1,299 |
| 2021 | Ownership or investment interest | 1 | $0 |
| 2020 | General payment | 26 | $376 |
| 2020 | Ownership or investment interest | 1 | $0 |
| 2019 | General payment | 28 | $471 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Acquisitions | 4 | $907,163 |
| Ownership or investment interest | 5 | $27,820 |
| Food and Beverage | 217 | $4,396 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $792 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | scPharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-11-12 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-21 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-10-15 | Senseonics, Incorporated | $36 | Food and Beverage | In-kind items and services | Eversense Device, Endocrinology | 2025 | |
| 2025-10-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage (2 payments) | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-09-23 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-08-15 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-08-14 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-23 | Esperion Therapeutics, Inc. | $28 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-07-15 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-07-09 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-06-30 | Abbott Laboratories | $23 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-06-20 | Edwards Lifesciences Corporation | $14,890 | Acquisitions | Cash or cash equivalent | 2025 | ||
| 2025-06-16 | Ascensia Diabetes Care Us Inc. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-10 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-06-04 | Edwards Lifesciences Corporation | $2,783 | Acquisitions | Cash or cash equivalent | 2025 | ||
| 2025-04-24 | Dexcom, Inc. | $21 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-04-22 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-04-22 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-10 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-02-04 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-01-16 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-01-14 | Dexcom, Inc. | $21 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-01-09 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2024-12-04 | Impulse Dynamics (USA) Inc. | $38 | Food and Beverage | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | 2024 | |
| 2024-12-03 | Boston Scientific Corporation | $15 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2024 | |
| 2024-11-22 | CVRx, Inc. | $186 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-11-21 | Edwards Lifesciences Corporation | $150 | Food and Beverage | In-kind items and services | SAPIEN 3 Ultra RESILIA Device, Transcatheter Heart Valves | 2024 | |
| 2024-11-20 | CVRx, Inc. | $4 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-11-12 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-11-06 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-11-05 | CVRx, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2024 | |
| 2024-10-17 | Inspire Medical Systems, Inc. | $23 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2024 | |
| 2024-10-10 | Edwards Lifesciences Corporation | $28 | Food and Beverage | In-kind items and services | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2024 | |
| 2024-09-25 | Mylan Specialty L.P. | $14 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2024 | |
| 2024-09-20 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2024 | |
| 2024-09-10 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-08-29 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-08-23 | Edwards Lifesciences Corporation | $693,296 | Acquisitions | Cash or cash equivalent | 2024 | ||
| 2024-08-19 | Edwards Lifesciences Corporation | $196,192 | Acquisitions | Cash or cash equivalent | 2024 | ||
| 2024-08-07 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-08-02 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2024 | |
| 2024-07-31 | Dexcom, Inc. | $21 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-07-31 | Kiniksa Pharmaceuticals International, plc | $15 | Food and Beverage | In-kind items and services | Arcalyst Drug, Not Applicable | 2024 | |
| 2024-07-23 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2024 | |
| 2024-07-19 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2024 | |
| 2024-06-28 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-06-25 | Dexcom, Inc. | $19 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-05-13 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $21 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-05-07 | Dexcom, Inc. | $23 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-04-25 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-04-17 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2024 | |
| 2024-03-27 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2024 | |
| 2024-03-14 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-03-05 | Dexcom, Inc. | $19 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2024-02-29 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-02-27 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $23 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-02-23 | Edwards Lifesciences Corporation | $18 | Food and Beverage | In-kind items and services | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2024 | |
| 2024-02-22 | Esperion Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2024 | |
| 2024-02-22 | Janssen Pharmaceuticals, Inc | $13 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2024 | |
| 2024-02-18 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2024 | |
| 2024-02-15 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $4 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-01-23 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-01-08 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-01-03 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2023-12-27 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $22 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2023 | |
| 2023-12-20 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $21 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2023 | |
| 2023-12-01 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-11-23 | Dexcom, Inc. | $24 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-11-20 | Abbott Laboratories | $170 | Food and Beverage | In-kind items and services | MITRACLIP Device, Vascular | 2023 | |
| 2023-11-10 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2023 | |
| 2023-10-25 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2023 | |
| 2023-09-26 | Mylan Specialty L.P. | $15 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2023 | |
| 2023-09-13 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2023 | |
| 2023-08-24 | Edwards Lifesciences Corporation | $27 | Food and Beverage | In-kind items and services | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2023 | |
| 2023-08-23 | Impulse Dynamics (USA) Inc. | $71 | Food and Beverage | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-08-22 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-08-22 | Impulse Dynamics (USA) Inc. | $18 | Food and Beverage | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-08-15 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-08-15 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 | |
| 2023-07-27 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-06-28 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | AFINION 2 Device, Rapid Diagnostics | 2023 | |
| 2023-06-27 | Abbott Laboratories | $7 | Food and Beverage | In-kind items and services | AFINION 2 Device, Rapid Diagnostics | 2023 | |
| 2023-06-27 | Abbott Laboratories | $4 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 | |
| 2023-06-27 | Abbott Laboratories | $1 | Food and Beverage | In-kind items and services | AFINION 2 Device, Rapid Diagnostics | 2023 | |
| 2023-06-27 | Abbott Laboratories | $0 | Food and Beverage | In-kind items and services | AFINION 2 Device, Rapid Diagnostics | 2023 | |
| 2023-06-20 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2023 | |
| 2023-06-15 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-05-23 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-05-19 | BIOTRONIK INC. | $70 | Food and Beverage | In-kind items and services | BIOMONITOR Device, Cardiology/Vascular Diseases | 2023 | |
| 2023-05-16 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-05-11 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2023 | |
| 2023-05-03 | Edwards Lifesciences Corporation | $29 | Food and Beverage | In-kind items and services | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | 2023 | |
| 2023-04-30 | Abbott Laboratories | $20 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 | |
| 2023-04-28 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2023 | |
| 2023-04-27 | Lilly USA, LLC | $43 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-04-18 | Dexcom, Inc. | $13 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-03-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-03-24 | Impulse Dynamics (USA) Inc. | $28 | Food and Beverage | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-03-22 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-03-10 | Impulse Dynamics (USA) Inc. | $17 | Food and Beverage | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | 2023 | |
| 2023-03-10 | IDORSIA PHARMACEUTICALS US INC | $14 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-03-03 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2023 | |
| 2023-03-01 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2023 | |
| 2023-02-27 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 2 Device, Diabetes Care | 2023 | |
| 2023-02-21 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 | |
| 2023-02-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-01-26 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-01-11 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2023 | |
| 2022-12-07 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-12-07 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2022 | |
| 2022-11-30 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2022 | |
| 2022-11-11 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2022 | |
| 2022-10-11 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-10-05 | Mylan Specialty L.P. | $18 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2022 | |
| 2022-09-27 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-09-22 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2022 | |
| 2022-09-14 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2022 | |
| 2022-08-15 | Mylan Specialty L.P. | $18 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2022 | |
| 2022-08-04 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-06-29 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2022 | |
| 2022-05-25 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2022 | |
| 2022-05-20 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-05-17 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-05-11 | Mylan Specialty L.P. | $13 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2022 | |
| 2022-04-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-04-19 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2022 | |
| 2022-04-14 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2022 | |
| 2022-03-01 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-02-17 | Mylan Specialty L.P. | $12 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2022 | |
| 2022-02-15 | Kowa Pharmaceuticals America, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2022 | |
| 2022-02-02 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | LEQVIO Drug, CARDIOVASCULAR | 2022 | |
| 2022-02-01 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2022 | |
| 2022-02-01 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $3 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2022 | |
| 2021-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-12-08 | Mylan Specialty L.P. | $16 | Food and Beverage | In-kind items and services | Yupelri Drug, Anticholinergics, Inhaled | 2021 | |
| 2021-11-04 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-11-02 | AstraZeneca Pharmaceuticals LP | $9 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-10-26 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-10-22 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-09-14 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-08-20 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-08-12 | Kowa Pharmaceuticals America, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2021 | |
| 2021-08-11 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2021 | |
| 2021-08-10 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-07-19 | Novartis Pharmaceuticals Corporation | $792 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2021 | |
| 2021-07-09 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-07-06 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-06-30 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-06-22 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-06-08 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-05-14 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-05-06 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-04-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-04-23 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-20 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-04-02 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-19 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2021 | |
| 2021-03-09 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-02-24 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2021 | |
| 2021-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2021 | |
| 2021-02-11 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2021 | |
| 2021-02-02 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2021 | |
| 2021-01-27 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-01-06 | Kowa Pharmaceuticals America, Inc. | $12 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2021 | |
| 2020-12-17 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2020 | |
| 2020-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | PRADAXA Drug, CARDIOVASCULAR | 2020 | |
| 2020-12-08 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-12-02 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-10-27 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-10-08 | Janssen Pharmaceuticals, Inc | $11 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-10-06 | Kowa Pharmaceuticals America, Inc. | $16 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-09-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | PRADAXA Drug, CARDIOVASCULAR | 2020 | |
| 2020-09-23 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-09-16 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-09-09 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2020 | |
| 2020-09-02 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-08-19 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-08-10 | Amarin Pharma, Inc. | $17 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-07-29 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | Corlanor Drug, Cardiology | 2020 | |
| 2020-07-21 | Amarin Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-06-30 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-06-23 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-05-28 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $14 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2020 | |
| 2020-05-05 | Kowa Pharmaceuticals America, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-03-12 | Kowa Pharmaceuticals America, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-03-05 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $3 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2020 | |
| 2020-03-03 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2020 | |
| 2020-02-20 | Amarin Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-02-13 | Kowa Pharmaceuticals America, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-02-11 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2019-11-12 | Amarin Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | Vascepa Drug, Hypertriglyceridemia | 2019 | |
| 2019-11-07 | Janssen Pharmaceuticals, Inc | $16 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-10-15 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-10 | Amarin Pharma, Inc. | $14 | Food and Beverage | In-kind items and services | Vascepa Drug, Hypertriglyceridemia | 2019 | |
| 2019-09-18 | Beckman Coulter, Inc. | $28 | Food and Beverage | In-kind items and services | AU480 Device, CHEMISTRY | 2019 | |
| 2019-09-18 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 |
The latest 200 records of 227.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-10-24 | ModernaTX, Inc. | ACCEL RESEARCH SITES-GA LLC | $750 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-10-24 | ModernaTX, Inc. | ACCEL RESEARCH SITES-GA LLC | $4,000 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-10-15 | ModernaTX, Inc. | ACCEL RESEARCH SITES-GA LLC | $93 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2025-06-18 | ModernaTX, Inc. | ACCEL RESEARCH SITES-GA LLC | $3,148 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | 2025 |
| 2024-09-18 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,000 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-08-01 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $5,011 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-06-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $15,035 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-06-06 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,000 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-31 | Novo Nordisk AS | Accel Research Sites | $1,950 | NN9535-4533 | 2024 |
| 2024-05-29 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $5,041 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-27 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $500 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-05-24 | Amgen Inc. | ACCEL RESEARCH SITE - LAKE OCONEE CLINICAL RESEARCH UNIT | $19,570 | OCEANa-Outcomes P3 CV | 2024 |
| 2024-05-06 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $500 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-03-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $16,036 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-03-21 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $5,070 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-03-04 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,000 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-02-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $400 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-02-26 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $3,034 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-02-12 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $600 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 |
| 2024-01-16 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $9,699 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2024 |
| 2023-12-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-14 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,766 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-12-14 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,424 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-12-14 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,424 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-12-14 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,424 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-12-14 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,424 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-12-13 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $70 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-13 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $3,552 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $846 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $1,500 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $1,895 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-30 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-30 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-30 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-30 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,766 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,424 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $1,766 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-28 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-22 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $200 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-22 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $3,000 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-22 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $400 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-20 | Janssen Pharmaceuticals, Inc | Accel Rsrch Sites | $6,650 | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncy | 2023 |
| 2023-11-17 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $500 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $1,481 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-11-03 | PFIZER INC. | Accel Research Sites GA LLC | $3,300 | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTO | 2023 |
| 2023-11-01 | Janssen Research & Development, LLC | Accel Rsrch Sites | $1,250 | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | 2023 |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-31 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-26 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-26 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-26 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $90 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-05 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-05 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-05 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-05 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-02 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $200 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-02 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $500 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-02 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $250 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-02 | Alnylam Pharmaceuticals Inc. | Accel Research Sites - GA, LLC | $650 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-10-02 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $400 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-10-02 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $220 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $55 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | Accel Research Sites Lake Oconee | $30 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
| 2023-09-26 | Janssen Research & Development, LLC | Accel Rsrch Sites | $2,342 | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | 2023 |
| 2023-09-22 | Novo Nordisk AS | Accel Research Sites | $500 | NN9535-4533 | 2023 |
| 2023-09-20 | Janssen Research & Development, LLC | Accel Rsrch Sites | $1,500 | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | 2023 |
| 2023-09-18 | Janssen Pharmaceuticals, Inc | Accel Rsrch Sites | $50 | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncy | 2023 |
| 2023-09-08 | Janssen Pharmaceuticals, Inc | Accel Rsrch Sites | $81 | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncy | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,053 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $700 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $20 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $700 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,053 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $801 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,053 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $700 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,053 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,053 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
| 2023-09-07 | ModernaTX, Inc. | ACCEL RESEARCH SITES - GA LLC | $2,262 | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Eatonton, GA, county Putnam County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Eatonton, GA | County Putnam County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 6,515 | 22,855 | 10,940,407 |
| Population, 2020 census P1 | 6,307 | 22,047 | 10,711,908 |
| Median age B01002 | 43.5 | 47.8 | 37.6 |
| Under 18 B01001 | 25.6% | 19.4% | 23.2% |
| 65 and over B01001 | 18.3% | 24.8% | 15.0% |
| Households B11001 | 2,521 | 10,435 | 4,074,366 |
| Foreign born B05002 | 11.3% | 7.6% | 11.2% |
| Median household income B19013 | $56,250 | $72,096 | $77,353 |
| Median family income B19113 | $64,229 | $90,545 | $93,754 |
| Per capita income B19301 | $36,658 | $48,458 | $40,924 |
| Poverty rate B17001 | 16.6% | 17.6% | 13.4% |
| Unemployment rate B23025 | 4.3% | 3.7% | 5.1% |
| Civilian labor force B23025 | 2,890 | 10,322 | 5,496,061 |
| Mean commute (minutes) B08013 | 23.3 | 31.1 | 28.3 |
| Bachelor's degree or higher B15003 | 20.4% | 31.1% | 34.9% |
| Housing units B25001 | 2,755 | 13,505 | 4,541,835 |
| Owner-occupied B25003 | 76.4% | 80.9% | 65.7% |
| Renters B25003 | 23.6% | 19.1% | 34.3% |
| Median home value B25077 | $167,400 | $249,300 | $303,300 |
| Median gross rent B25064 | $954 | $1,002 | $1,393 |
| White, not Hispanic B03002 | 35.5% | 64.5% | 49.1% |
| Black B03002 | 44.7% | 22.0% | 30.7% |
| Hispanic or Latino B03002 | 14.8% | 7.2% | 11.0% |
| Asian B03002 | 1.0% | 2.0% | 4.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Eatonton, GA.
Comments